Hays Advisory LLC cut its position in Five Prime Therapeutics Inc. (NASDAQ:FPRX) by 9.3% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 123,148 shares of the company’s stock after selling 12,574 shares during the period. Five Prime Therapeutics accounts for approximately 1.1% of Hays Advisory LLC’s portfolio, making the stock its 24th largest position. Hays Advisory LLC owned 0.46% of Five Prime Therapeutics worth $6,464,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in FPRX. Acadian Asset Management LLC boosted its position in shares of Five Prime Therapeutics by 112.1% in the second quarter. Acadian Asset Management LLC now owns 1,094,368 shares of the company’s stock worth $45,250,000 after buying an additional 578,411 shares in the last quarter. FMR LLC raised its stake in shares of Five Prime Therapeutics by 24.1% in the second quarter. FMR LLC now owns 2,817,208 shares of the company’s stock worth $116,492,000 after buying an additional 547,808 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Five Prime Therapeutics during the second quarter worth about $19,498,000. Vanguard Group Inc. raised its stake in shares of Five Prime Therapeutics by 43.5% in the second quarter. Vanguard Group Inc. now owns 1,472,276 shares of the company’s stock worth $60,877,000 after buying an additional 446,311 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Five Prime Therapeutics by 28.5% in the second quarter. State Street Corp now owns 1,057,836 shares of the company’s stock worth $43,741,000 after buying an additional 234,648 shares during the last quarter. 91.16% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics Inc. (NASDAQ:FPRX) traded up 1.24% during trading on Monday, reaching $58.72. 278,670 shares of the company’s stock traded hands. The company has a 50 day moving average price of $51.16 and a 200-day moving average price of $46.92. The company has a market cap of $1.59 billion, a PE ratio of 6.56 and a beta of 4.48. Five Prime Therapeutics Inc. has a 12-month low of $28.01 and a 12-month high of $59.58.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.21. Five Prime Therapeutics had a net margin of 64.94% and a return on equity of 59.23%. The firm earned $6.70 million during the quarter, compared to analysts’ expectations of $7.50 million. During the same period last year, the company earned ($0.93) EPS. The business’s quarterly revenue was up 13.6% on a year-over-year basis. On average, equities research analysts forecast that Five Prime Therapeutics Inc. will post ($2.18) EPS for the current fiscal year.

A number of equities research analysts have issued reports on FPRX shares. Jefferies Group set a $60.00 price target on Five Prime Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 5th. Leerink Swann reiterated an “outperform” rating and issued a $58.00 price target (up previously from $45.00) on shares of Five Prime Therapeutics in a research note on Monday, August 8th. Citigroup Inc. started coverage on Five Prime Therapeutics in a research note on Tuesday, October 25th. They issued a “buy” rating and a $65.00 price target for the company. Finally, Credit Suisse Group AG reiterated a “buy” rating and issued a $54.00 price target on shares of Five Prime Therapeutics in a research note on Monday, November 7th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Five Prime Therapeutics presently has a consensus rating of “Buy” and an average price target of $54.43.

In related news, Director Peder Jensen sold 8,130 shares of the stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $55.30, for a total transaction of $449,589.00. Following the completion of the transaction, the director now owns 4,065 shares of the company’s stock, valued at approximately $224,794.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William R. Ringo sold 500 shares of the stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $52.00, for a total transaction of $26,000.00. Following the transaction, the director now directly owns 500 shares of the company’s stock, valued at approximately $26,000. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by insiders.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

5 Day Chart for NASDAQ:FPRX

Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.